Download the Free Prime PubMed App to your smartphone or tablet.

Available for iPhone or iPad:

Unbound PubMed app for iOS iPhone iPadAlso Available:
Unbound PubMed app for Android

Available for Mac and Windows Desktops and laptops:

Unbound PubMed app for WindowsUnbound PubMed app for MAC OS Yosemite Macbook Air pro
2,678 results
  • Cost-minimization analysis of alemtuzumab compared to fingolimod and natalizumab for the treatment of active relapsing-remitting multiple sclerosis in the Netherlands. [Journal Article]
  • JMJ Med Econ 2018 Jun 18; :1-16
  • Piena MA, Heisen M, … Uitdehaag BMJ
  • CONCLUSIONS: No treatment discontinuation and associated switching between treatments were incorporated. Consequences of JC virus seropositivity while continuing natalizumab treatment (e.g. additional monitoring), were omitted from the base case.The current cost-minimization analysis demonstrates that, from the Dutch healthcare perspective, treating active RRMS patients with alemtuzumab results in cost savings compared to second-line alternatives fingolimod and natalizumab from approximately 3 years since treatment initiation onwards. After 5 years, alemtuzumab's cost savings are estimated at €30k compared to fingolimod and €43k compared to natalizumab.
  • [New aspects of immunotherapy in multiple sclerosis]. [Review]
  • NNervenarzt 2018 Jun 07
  • Pape K, Zipp F, Bittner S
  • The spectrum of therapeutic options for immunotherapy of multiple sclerosis is continuously broadening. After the approval of cladribine and ocrelizumab in Europe, two new drugs are now available wit...
  • Alemtuzumab-induced thyroid dysfunction exhibits distinctive clinical and immunological features. [Journal Article]
  • JCJ Clin Endocrinol Metab 2018 Jun 06
  • Pariani N, Willis M, … Moran C
  • CONCLUSIONS: Contrary to published literature, we have recorded frequent occurrence of GD that required definitive or prolonged antithyroid drug treatment. Furthermore, fluctuating thyroid status in GD and unexpectedly high frequency of TRAb-positive hypothyroidism suggested changing activity of TRAb in this clinical context; we have documented the existence of both blocking and stimulating TRAb in these patients.
  • [Alemtuzumab therapy 2017]. [Review]
  • ISIdeggyogy Sz 2017 Nov 30; 70(11-12):371-380
  • Biernacki T, Bencsik K, … Vécsei L
  • Multiple sclerosis (MS) is a chronic, immune-mediated disease of the central nervous system comprising of inflammation, demyelinisation and neurodegeneration. The natural history of MS is heterogenou...
New Search Next